IMpower133 is a double-blind, placebo-controlled, phase 3 trial where treatment naïve patients with ES-SCLC were randomly assigned (1:1 ratio) to receive carboplatin and etoposide with or without atezolizumab, an anti-PD-L1 antibody (4). The gene discussed is CD274; the disease is small cell lung carcinoma.